HYPERTENSION IN CKD MARKET ANALYSIS

The Global Hypertension in CKD Market is estimated to be valued at US$ 254.2 Mn  in 2023 and is expected to exhibit a CAGR of 10.7% during the forecast period (2023-2030).

Analysts’ Views on Global Hypertension in CKD Market :

 Hypertension is a common comorbidity in patients with chronic kidney disease (CKD) and is associated with poor cardiovascular and renal outcomes. Management of hypertension in CKD patients is challenging due to complications like volume overload, vascular stiffness, and activation of the renin-angiotensin system. Key drivers of the hypertension in CKD market include the rising prevalence of diabetes and obesity which increase CKD risk, growing elderly population more susceptible to CKD, and improved diagnosis and detection of CKD. However, lack of awareness of CKD, poor access to healthcare in developing regions, and high cost of CKD treatments hinders the growth of the market.

Figure 1. Global Hypertension in CKD Market Share (%), By Drug Class 2023

To learn more about this report, request sample copy

Global Hypertension in CKD Market – Drivers

• Increasing collaboration for conducting research and development activities: Increasing collaboration for conducting research and development activities is expected to propel the growth of the global hypertension in CKD market over the forecast period. For instance, in March 2021, Fresenius Medical Care AG & Co. KGaA, a Germany-based global healthcare company, announced a three-way merger with InterWell Health, the leading physician organization driving innovation in the kidney care space in the U.S., and Cricket Health, a U.S. provider of value-based kidney care with a leading patient engagement and data platform, entered into a binding agreement to create an independent new company. The merger brings together Fresenius Health Partners’ expertise in kidney care value-based contracting and performance, InterWell Health’s clinical care models and strong network of 1,600 nephrologists, and Cricket Health’s tech-enabled care model that utilizes its proprietary informatics, StageSmart, and patient engagement platforms to create an innovative, stand-alone entity poised to transform kidney care.
• Increasing prevalence of chronic kidney diseases: Increasing prevalence of chronic kidney diseases is expected to increase the demand for new treatment options, thereby driving the global hypertension in CKD market growth. For instance, according to the Kidney International Supplements article ‘Epidemiology of chronic kidney disease: an update 2022 published in March 2022, Chronic kidney diseases affect around 10% of the general population worldwide, amounting to 800 Mn individuals globally. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and people experiencing diabetes mellitus and hypertension. Chronic kidney disease represents an especially large burden in low- and middle-income countries, which are least equipped to deal with its consequences. Chronic kidney disease has emerged as one of the leading causes of mortality worldwide.

Figure 2. Global Hypertension in CKD Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Hypertension in CKD Market - Regional Analysis

Among regions, North America is expected to hold a dominant position in the global hypertension in CKD market, owing to the reimbursement policy for chronic kidney diseases in the region. For instance, the Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services, announced the new Medicare model for end-stage renal disease (ESRD), which is also called the last stage of the chronic kidney disease. The model is the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model. The model encourages increased use of home dialysis and kidney transplants to help improve the quality of life of Medicare beneficiaries with ESRD. Moreover, this model was implemented on January 1, 2021 and due to the implementation of the model, US$23 Mn was saved over a period of five and a half years.

Furthermore, Europe is also estimated to witness significant growth in the hypertension in CKD market, owing to the increasing prevalence of chronic kidney diseases in the region. For instance, according to an article published in the Lancet Journal in 2022, increasing prevalence of CKD was reported in 2021 in different regions of Europe.

Global Hypertension in CKD Market – Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems with the transportation of things from one place to another.
• However, the COVID-19 pandemic had a positive impact on the global hypertension in CKD market , owing to a reduction in bed and operating room capacity, which further led to considerable delays in urgent and semi-elective surgical interventions. According to an Indian Journal of Nephrology June 2020 publication, ‘Chronic Kidney Disease and Hypertension with Reference to COVID-19’ It is anticipated that few patients with CKD will experience episodes of acute kidney injury (AKI) following the COVID-19 infection, SARS-Cov-2 may affect the kidney directly through angiotensin-converting enzyme 2 (ACE2) receptors, causing direct injury and glomerular injury. 

Global Hypertension in CKD Market Segmentation:

The global hypertension in CKD market report is segmented by drug class type, by distribution channel and by region.

• By drug class, the market is segmented into Diuretics, RAS blockade, β-blockers, calcium channel blockers and others (α-Blockers, Vasodilators, Proteinuria, etc.). Out of which, the RAS blockade is expected to hold a dominant position in the global hypertension in CKD market during the forecast period, and this is attributed to recent product approvals and launches.
• By distribution channel, the market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies is expected to dominate the market over the forecast period, and this is attributed to the prompt treatment and distribution from hospitals that can lead to proper recovery.
• By Region,  the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa Out of which, North America is expected to dominate the market over the forecast period, and this is attributed to the increasing prevalence of hypertension and CKD patients in North America.
• Among all the segmentation, the drug class is expected to dominate the market over the forecast period and this is attributed to increasing preference of RAS Inhibitors by nephrologists.

Global Hypertension in CKD Market - Cross Sectional Analysis:

Key players are focusing on research and development to improve the safety and efficacy of the drugs having drug class’ RAS blockade in North America region. For instance, on January 24, 2023, Novartis AG, a U.S. based global pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for phase III trial for Jardiance, which is being investigated to reduce the risk of kidney disease progression or cardiovascular death in adults with CKD.

Global Hypertension in CKD Market : Key Developments

• On February 10, 2023, Bayer AG, a German multinational pharmaceutical and biotechnology company, announced an expanded indication from the European Commission granted for a label extension for Kerendia (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study.
• In March 2022, Zydus Lifesciences Ltd., an India-based global lifesciences company, announced that it had received approval for its New Drug Application (NDA) from the Central Drugs Standard Control Organization (CDSCO) for Oxemia indicated for the treatment of Desidustat, a first-of-its-kind oral treatment in India for anemia associated with chronic kidney disease.
• In May 2022, KBP Biosciences Holdings Limited a global biotechnology research & development ccompany,  signed an exclusive licensing agreement with pharmaceutical company Xelphar to commercialize KBP-1001 in several European countries upon regulatory approval. This key partnership expanded KBP's international reach and marks its first move into the European market.
• In July 2022, Kissei Pharmaceutical Co., a Japan based research-based pharmaceutical company, announced licensing agreement with Otsuka Pharmaceutical to develop and commercialize IRENE for the treatment of hypertension in Europe. This agreement provides potential expansion into an important international market upon approval.

Global Hypertension in CKD Market : Key Trends

• Rising number of product launches and approvals: Increasing product launches and approvals by key players in the market is expected to drive the growth of the global hypertension in CKD market over the forecast period. For instance, on February 1, 2023, GSK plc, a U.K-based multinational pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the once-a-day treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months and are contraindicted for hypertension.

Global Hypertension in CKD Market : Opportunities

• Emerging novel therapies and combination drugs: There are many bovel therapies and combination durgs being investigated for the treatment of Hypertension in CKD Endothelin Receptor Antagonists: These drugs block the action of endothelin, a substance that constricts blood vessels and raises blood pressure. For instance, in May, 2022 Chinook Therapeutics, a clinical-stage immunotherapy company, presented data from phase 2 clinical trials for the drug Atrasentan which has shown promise in reducing proteinuria and blood pressure in CKD patient.

Global Hypertension in CKD Market : Restraint

Lack of awareness about chronic kidney disease

• Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the global hypertension in CKD market over the forecast period. Despite the attempts made by governments in order to increase awareness among the population about chronic kidney disease (CKD) through different ways, such as the dissemination of clinical practice guidelines and recommendations for patients with CKD or its risk factors, community awareness on events such as World Kidney Day, and free screening for high-risk individuals such as the Kidney Early Evaluation Program (KEEP), it has been found that the awareness of CKD among the population remains unacceptably low. For instance, in December 2022, according to the study published in the BMC Public Health, for chronic kidney disease evaluation, it was reported that the people in Australia have a very poor understanding of chronic kidney disease (CKD), and only half of the participants knew about the availability of medications and also their role in slowing down the worsening of CKD.
• However, there are Public Awareness Campaigns organized from Health organizations and governments can launch campaigns to educate the public about the risks and symptoms of CKD.

Global Hypertension in CKD Market  - Key Players

Major players operating in the global hypertension in CKD market  include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBPBiosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.

Definition: The pathophysiology of hypertension in CKD is complex, with multiple factors contributing, including decreased nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, hormone activation, including the renin-angiotensin-aldosterone system, and endothelial dysfunction.